【摘要】：正卒中已成為世界第二大致死原因和第三大致殘原因,其中缺血性卒中占80%~([1-3])。而在急性缺血性卒中發(fā)病機(jī)制中,血小板活化在導(dǎo)致血栓形成,并進(jìn)一步阻塞血管致缺血事件中起著非常重要的作用。因此,選擇性快速抑制血小板聚集非常關(guān)鍵,不但能夠起到溶解血栓作用,且能夠預(yù)防血栓再次形成~([4])。替羅非班是一種選擇性非肽類血小板糖蛋白Ⅱb/Ⅲa受體拮抗劑,能通過與血小板表面Ⅱb/Ⅲa受體結(jié)合,阻斷其與纖維蛋白原配體特異性結(jié)合,從
[Abstract]:Positive stroke has become the second leading cause of death and the third major cause of disability in the world, in which ischemic stroke accounts for 80 ~ (1-3). In the pathogenesis of acute ischemic stroke, platelet activation plays a very important role in thrombosis and further occlusion of vascular ischemic events. Therefore, selective and rapid inhibition of platelet aggregation is crucial, not only to dissolve thrombus, but also to prevent thrombus from reforming. Tirofiban is a selective non-peptide platelet glycoprotein 鈪，

本文編號：2378017